{'fraction_non_alphanumeric': 0.061529933481152994, 'fraction_numerical': 0.07095343680709534, 'mean_word_length': 5.057046979865772, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 5, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Polymorphisms of TNF and IL‐10 genes and clinical outcome of patients with chronic lymphocytic leukemia

Genetic variations in tumor necrosis factor (TNF) and interleukin‐10 (IL‐10) were reported to influence susceptibility to and outcome of patients with non‐Hodgkin lymphoma. Therefore, we investigated whether single nucleotide polymorphisms in TNF and IL‐10 may play a role in the clinical course of patients with chronic lymphocytic leukemia (CLL). TNF‐308G>A, IL‐10‐3575T>A, and IL‐10‐1082A>G seem to be functionally relevant, were genotyped in 292 previously untreated patients with CLL. The control group consisted of 192 randomly selected blood donors. The patients carrying TNF‐308GG and IL‐10‐1082AA genotypes presented a higher 3‐year treatment‐free survival (56.6 vs. 40.6%, P = 0.05) as well as a 10‐year overall survival (OS) rates (92.3 vs. 57.6%, P = 0.005) than those with other TNF‐308 and IL‐10‐1082 genotype combinations. Multivariate analysis demonstrated the Rai stage (P = 0.0002), IGHV mutation status (P = 0.01), TNF‐308G>A (P = 0.03), and TNF/IL‐10 polymorphism‐based risk groups (P = 0.05) to be independent factors predicting OS. When the mutated IGHV patients were analyzed, the homozygotes TNF‐308GG and IL‐10‐1082AA presented a higher 10‐year OS rate than those carrying other TNF‐308 and IL‐10‐1082 genotypes (100 vs. 67.7%, P = 0.01). In the unmutated IGHV patients, only the TNF‐308G>A polymorphism influenced OS. The genetic variations in TNF and IL‐10 genes work as independent predictors of survival and may play a role in the clinical course of CLL. It suggests inherited ability of the host to shift the balance between the Th1 and Th2 response, which in turn might contribute to the pathogenesis and prognosis of B‐cell malignancies. © 2012 Wiley Periodicals,Inc.